| 영문 | dopamine | 한글 | 도파민 |
|---|---|---|---|
| 설명 | 히드록시티라민으로서 생리활성 아민-카테콜아민의 일종. 분자식은C18H11NO2, 분자량은 153.18이다. 동식물에 존재하는 아미노산의 하나로, 자외선 작용으로 티로신에서 형성되거나 L-Dopa의 탈탄산에 의해 체내에서 생산된다. 멜라닌 색소 합성 과정의 중간 물질로 콩과 식물에 저장되어 있다. 뇌신경 세포의 흥분 전달에 중요한 구실을 한다. 도파민β-산화효소의 작용에 의해 노르아드레날린이 된다. 부신수질-뇌-교감신경계-폐-작은창자-간 등에도 많이 포함되어 있다. 파킨슨 증후군의 경우 뇌 안의 도파민 량이 감소되며, 뇌줄기의 줄무늬체에는 노르아드레날린보다 도파민이 다량 포함되어 있음을 볼 수 있다는 점에서 도파민 자체가 이른바 카테콜아민을 함유하는 작동성 뉴런의 신경전달물질로서 작용하고 있음이 분명해졌다. |
||
| DBH | Dopamine-Beta(β)-Hydroxylase |
|---|---|
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
| DBH | dopamine beta-hydroxylase |
| DM | defined medium; dermatomyositis; Descemet's membrane; dextromaltose; dextromethorphan; diabetes mell... |
| DOPAMINE | dihydroxyphenylethylamine |
| DA | Dopamine agonists |
|---|---|
| GnRHa | Gonadotrophin releasing hormone agonists |
| DA | 14C-dopamine |
| DA | 3)H]-dopamine |
| [(3)H]-DA | 3)H]-dopamine |
striate body neurosis
| dopamine agonists | Drugs that bind to and activate dopamine receptors. (12 Dec 1998) |
|---|
| adrenergic agonists | Drugs that bind to and activate adrenergic receptors. (12 Dec 1998) |
|---|---|
| adrenergic alpha-agonists | Drugs that selectively bind to and activate alpha adrenergic receptors. (12 Dec 1998) |
| adrenergic beta-agonists | Drugs that selectively bind to and activate beta-adrenergic receptors. (12 Dec 1998) |
| gaba agonists | Drugs that bind to and activate gaba receptors (receptors, gaba). (12 Dec 1998) |
| receptors, dopamine | Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behaviour of cells. (12 Dec 1998) |
| receptors, dopamine d1 | A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, by their mode of action. (12 Dec 1998) |
| receptors, dopamine d2 | A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, their mode of action. (12 Dec 1998) |
| cholinergic agonists | Drugs that bind to and activate cholinergic receptors. (12 Dec 1998) |
| myeloablative agonists | Agents that destroy bone marrow activity. They are used to prepare patients for bone marrow or stem cell transplantation. (12 Dec 1998) |
| serotonin agonists | Agents that have an affinity for serotonin receptors and are able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. These compounds are used as antidepressants, anxiolytics, and in the treatment of migraine. (12 Dec 1998) |
| nicotinic agonists | Drugs that bind to and activate nicotinic cholinergic receptors (receptors, nicotinic). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarising blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission. (12 Dec 1998) |
| dopamine | <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline. Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min. Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias (15 Mar 2000) |
| dopamine agents | Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (12 Dec 1998) |
| dopamine antagonists | Drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (antipsychotic agents) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as antiemetics, in the treatment of tourette syndrome, and for hiccup. (12 Dec 1998) |
| dopamine beta-hydroxylase | <enzyme> Chemical name: 3,4-Dihydroxyphenethylamine, ascorbate:oxygen oxidoreductase (beta-hydroxylating) Registry number: EC 1.14.17.1 (12 Dec 1998) |
Synonyms : Agonists, Dopamine Receptor, Agonists, Dopaminergic, Dopamine Agonist, Dopamine Receptor Agonist, Dopaminergic Agonist, Receptor Agonists, Dopamine, Agonist, Dopamine, Agonist, Dopamine Receptor, Agonist, Dopaminergic, Agonists, Dopamine
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|